Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Shire and Boston Children’s Hospital Enter into Broad Research Collaboration

Published: Tuesday, November 27, 2012
Last Updated: Tuesday, November 27, 2012
Bookmark and Share
Shire PLC and Boston Children’s Hospital today announced a three-year, broad research collaboration in rare diseases.

The goal of the collaboration is to develop novel therapies to treat a number of rare pediatric diseases with high unmet medical need, thereby leveraging Boston Children’s research expertise and Shire’s development and commercialization capabilities. The partnership underscores Shire’s long-term commitment to bring innovative therapies to patients with rare diseases worldwide.

Under the terms of the agreement, Shire will make an initial upfront payment to Boston Children’s and will have the opportunity to fund selected research programs. The emphasis will be on opportunities that have the potential to deliver a development candidate in less than three years from project initiation. Following the completion of these programs, Shire will have an exclusive option to enter into a licensing agreement for each program. Upon entering into any subsequent licensing agreement, Boston Children’s will be eligible to receive certain development and commercial milestone payments, as well as royalties on product sales from Shire. Shire will have the primary responsibility for any further clinical development and commercialization of products arising from the collaboration. The agreement, negotiated on the Boston Children’s side by its Technology & Innovation Development Office, represents a flexible structure that aligns the parties according to their strengths.

“As a leader in rare diseases, Shire is pleased to enter into this innovative collaboration with Boston Children’s, which joins together leaders in academia and industry to advance pioneering research from the lab to the clinic,” said Dr. Philip J. Vickers, Global Head of Research and Development, Shire HGT. “Shire has a deep commitment to patients with rare diseases, and our developmental expertise combined with Boston Children’s research capabilities should enable an acceleration of our discovery and development efforts. Our collaboration with Boston Children’s is an ideal example of how we advance these goals."

“We are excited about the potential that the collaboration with Shire represents,” said Alan Beggs, PhD, Director of the Manton Center for Orphan Disease Research at Boston Children’s. “Boston Children’s brings the research infrastructure to make the foundational discoveries about these diseases and our clinicians know the patients and their needs. Partnering with Shire’s drug development capabilities represents a powerful combination that we hope will facilitate the development of new classes of therapy to ultimately benefit patients.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

“Deep sequencing” Picks up Hidden Causes of Brain Disorders
New approach complements whole-genome and whole-exome sequencing.
Wednesday, August 20, 2014
Microscopic Packets of Stem Cell Factors could be Key to Preventing Lung Disease in Babies
Research suggests that exosomes alone could protect infants' lungs from dangerous inflammation.
Monday, November 05, 2012
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Editing Gene Mutations in Anemia
Researchers successfully use a new gene editing strategy to correct mutations that cause a form of anemia.
Genes Help Track Odd Migrations of Zika Mosquitoes
Study shows that mosquitoes carrying Zika virus or Dengue fever a genetically distinct around the world.
Nanomedicine Aims to Improve HIV Drug Therapies
New research aims to improve the administration and availability of drug therapies to HIV patients using nanotechnology.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
Driving Mosquito Evolution to Fight Malaria
Researchers propose insect repellent in conjunction with insecticides to extend current insecticide lifetime.
Lab-on-a-Chip to Help Detect Cancer
In this podcast, we speak to Gustavo Stolovitsky to learn about his career and the work he is doing at IBM Research.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos